[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","commit":"f7782c9f5f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on a further thirty companies","file":"src/data/spikes/breast-her2-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.hengrui.com\" }]"}]},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/breast-her2-positive.ts","type":"changed","fields":[{"field":"tldr","before":"\"China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.\"","after":"\"Jiangsu Hengrui is China's largest oncology pharma, maker of pyrotinib and the HER2 ADC trastuzumab rezetecan, and one of the biggest out-licensers of Chinese assets.\""}]},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-her2-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"ticker"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"drugs"},{"field":"cancers"}]}]